



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/577,940

07/12/2006

Braj Lohray

GRT/4062-190

5252

23117 7590 09/17/2010
NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VA 22203

EXAMINER

CHANG, CELIA C

ART UNIT

PAPER NUMBER

1625

MAIL DATE

DELIVERY MODE

09/17/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Art Unit: 1625

-ATTACHMENT TO ADVISORY—

An after final amendment and response filed by applicants dated Sept. 7, 2010 with a declaration under 37 CFR 1.132 have been considered carefully.

The newly amended claims 10-21 and new claims 25-28 will NOT be entered for the following reason:

1. Claims 10-21 and 25-28 do not obviate the new matter rejection but would be considered to contain new matter. Please note that the claimed product is clopidogel bisulfate form I with a m.p. $184 \pm 3^{\circ}\text{C}$. The 132 declaration provided five products which have:

	m.p. $^{\circ}\text{C}$
Exp. 1	178-180
Exp. 2	178-180
Exp. 3	182-186
Exp. 4	205-208
Exp. 5	205-212

Please note that none of the product is the claimed product with m.p. of $184 \pm 3^{\circ}\text{C}$. The 132 declaration supports that the claims are new matter not the disclosed product.

2. The above evidence also support the 112 enablement rejection since the process as declared did not make the claimed product.
3. After removal of new matter, the claims (3/11/10 version) are still anticipated by US 6,429,210.

/Celia Chang/

Primary Examiner

AU 1625